BioLine RX Ltd (BLRX) — Net Asset Quality Index
BioLine RX Ltd (BLRX) has a Net Asset Quality Index of 49.1% as of September 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of ILA39.80 Million minus total liabilities of ILA20.27 Million yields net assets of ILA19.53 Million. A higher index indicates a stronger, lower-leverage balance sheet. Check BioLine RX Ltd asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Quality Index
Net Assets
Total Assets
Total Liabilities
BioLine RX Ltd Net Asset Quality Index Over Time (2005–2024)
This chart shows how BioLine RX Ltd's Net Asset Quality Index has evolved across 20 annual periods from 2005 to 2024. As of September 2025, the index stands at 49.1%, representing net assets of ILA19.53 Million against total assets of ILA39.80 Million ILA. See BioLine RX Ltd working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Annual Net Asset Quality Index for BioLine RX Ltd (2005–2024)
The table below presents the year-by-year Net Asset Quality Index for BioLine RX Ltd from 2005 to 2024, covering 20 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see market value of BioLine RX Ltd.
| Year | Quality Index | Net Assets (ILA) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 34.6% | ILA13.46 Million | ILA38.91 Million | ILA25.45 Million | ▲ +13.9 pp |
| 2023 | 20.7% | ILA13.22 Million | ILA63.92 Million | ILA50.70 Million | ▼ -45.9 pp |
| 2022 | 66.6% | ILA50.84 Million | ILA76.38 Million | ILA25.54 Million | ▼ -17.1 pp |
| 2021 | 83.7% | ILA68.09 Million | ILA81.39 Million | ILA13.30 Million | ▲ +37.1 pp |
| 2020 | 46.6% | ILA22.03 Million | ILA47.29 Million | ILA25.26 Million | ▼ -15.7 pp |
| 2019 | 62.3% | ILA33.38 Million | ILA53.57 Million | ILA20.19 Million | ▼ -11.2 pp |
| 2018 | 73.5% | ILA41.32 Million | ILA56.23 Million | ILA14.91 Million | ▼ -13.3 pp |
| 2017 | 86.7% | ILA52.88 Million | ILA60.97 Million | ILA8.08 Million | ▼ -3.2 pp |
| 2016 | 90.0% | ILA35.03 Million | ILA38.94 Million | ILA3.91 Million | ▼ -2.8 pp |
| 2015 | 92.8% | ILA47.61 Million | ILA51.30 Million | ILA3.69 Million | ▲ +5.0 pp |
| 2014 | 87.8% | ILA31.77 Million | ILA36.17 Million | ILA4.40 Million | ▲ +29.3 pp |
| 2013 | 58.6% | ILA11.68 Million | ILA19.95 Million | ILA8.27 Million | ▼ -3.0 pp |
| 2012 | 61.6% | ILA14.97 Million | ILA24.31 Million | ILA9.34 Million | ▼ -15.2 pp |
| 2011 | 76.8% | ILA22.53 Million | ILA29.34 Million | ILA6.81 Million | ▼ -8.5 pp |
| 2010 | 85.3% | ILA131.96 Million | ILA154.61 Million | ILA22.65 Million | ▲ +11.3 pp |
| 2009 | 74.1% | ILA117.94 Million | ILA159.17 Million | ILA41.23 Million | ▲ +6.4 pp |
| 2008 | 67.7% | ILA78.39 Million | ILA115.73 Million | ILA37.34 Million | ▼ -20.4 pp |
| 2007 | 88.2% | ILA183.25 Million | ILA207.88 Million | ILA24.63 Million | ▲ +94.3 pp |
| 2006 | -6.2% | ILA-1.25 Million | ILA20.12 Million | ILA21.37 Million | ▼ -68.2 pp |
| 2005 | 62.0% | ILA12.77 Million | ILA20.59 Million | ILA7.83 Million | — |